Omeros (OMER) Announces Additional Positive OMS721 Phase 2 Data

Go back to Omeros (OMER) Announces Additional Positive OMS721 Phase 2 Data

Omeros (OMER) PT Raised to $70 at Wedbush

August 18, 2015 1:10 PM EDT

Wedbush analyst Liana Moussatos reiterated an Outperform rating and raised her price target on Omeros Corp. (NASDAQ: OMER) to $70.00 (from $61.00), saying OMS721 achieved proof of concept for aHUS in the firm's view.

Moussatos commented, "With significant normalization of platelet counts and other TMA parameters... More

Omeros (OMER) OMS721 Shows Compelling Activity, Cowen Says

August 18, 2015 8:57 AM EDT

Cowen analyst Yatin Suneja reiterated an Outperform rating on Omeros Corp. (NASDAQ: OMER) after OMS721 shows compelling activity.

Suneja commented, "OMER reported additional Ph. II data on OMS721. All 3 aHUS patients treated with 721 showed normalization of platelet counts and improvement in disease activity... More

Omeros (OMER) Plans to File Patent Infringment Suit vs. Par Pharma

August 17, 2015 7:01 AM EDT

Omeros (NASDAQ: OMER) in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC (Par) in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is approved by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce... More